MDT-AP-1369
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 32.04
- os_event
- false
- age_years
- 3.03
- sex
- M
- new_clusters
- C1
- umap1_2d
- 4.203254897
- umap2_2d
- 0.618776409
- umap1_3d
- 0.799210085
- umap2_3d
- -3.647204508
- umap3_3d
- -1.5987096
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.490
- TNFA_SIGNALING_VIA_NFKB+0.420
- HYPOXIA+0.410
- PROTEIN_SECRETION+0.360
- HEME_METABOLISM+0.340
- INFLAMMATORY_RESPONSE+0.330
- IL6_JAK_STAT3_SIGNALING+0.300
- P53_PATHWAY+0.290
- NOTCH_SIGNALING+0.270
- MTORC1_SIGNALING+0.260
Top 10 suppressed
- E2F_TARGETS-0.470
- MYC_TARGETS_V2-0.380
- G2M_CHECKPOINT-0.370
- MYC_TARGETS_V1-0.360
- SPERMATOGENESIS-0.240
- KRAS_SIGNALING_DN-0.220
- PANCREAS_BETA_CELLS-0.160
- ALLOGRAFT_REJECTION-0.070
- OXIDATIVE_PHOSPHORYLATION-0.060
- ESTROGEN_RESPONSE_LATE-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_4A45GGSW | pilocytic astrocytoma | — | 0.864 |
| 2 | MNG902 | — | — | 0.860 |
| 3 | R66 | — | — | 0.840 |
| 4 | c2ccc6b3-34d8-47c5-9367-cc53aad1622e | — | — | 0.825 |
| 5 | BS_Q79NP5YY | pilocytic astrocytoma | — | 0.821 |
| 6 | BS_42Y3YANN | pilocytic astrocytoma | — | 0.812 |
| 7 | BS_FJWZ3M7V | low-grade glioma | — | 0.811 |
| 8 | TCGA-50-5939-01A-11R-1628-07 | — | cohortA1 | 0.809 |
| 9 | 9A593453-3B4C-4557-84BF-E9E902AA0F3F | — | — | 0.804 |
| 10 | BS_N1E0H8YQ | low-grade glioma | — | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.490 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.420 | Inavolisib | — uncovered |
| HYPOXIA | 0.410 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.340 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.190 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |